Wall Street analysts expect Thermo Fisher Scientific (TMO) to post quarterly earnings of $6.40 per share in its upcoming report, which indicates a year-over-year increase of 10.5%. Revenues are expected to be $11.92 billion, up 7.2% from the year-ago quarter.
Over the last 30 days, there has been an upward revision of 0.2% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.
Prior to a company's earnings announcement, it is crucial to consider revisions to earnings estimates. This serves as a significant indicator for predicting potential investor actions regarding the stock. Empirical research has consistently demonstrated a robust correlation between trends in earnings estimate revision and the short-term price performance of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
With that in mind, let's delve into the average projections of some Thermo Fisher metrics that are commonly tracked and projected by analysts on Wall Street.
Analysts' assessment points toward 'Revenues- Laboratory Products and Biopharma Services' reaching $6.56 billion. The estimate points to a change of +9.9% from the year-ago quarter.
The consensus estimate for 'Revenues- Specialty Diagnostics' stands at $1.14 billion. The estimate points to a change of -3% from the year-ago quarter.
Analysts forecast 'Revenues- Life Sciences Solutions' to reach $2.85 billion. The estimate indicates a change of +10.3% from the prior-year quarter.
Based on the collective assessment of analysts, 'Revenues- Analytical Instruments' should arrive at $1.95 billion. The estimate indicates a change of +2.8% from the prior-year quarter.
The consensus among analysts is that 'Revenue Growth - Organic' will reach 4.2%. Compared to the current estimate, the company reported 3.0% in the same quarter of the previous year.
View all Key Company Metrics for Thermo Fisher here>>>Thermo Fisher shares have witnessed a change of +5.8% in the past month, in contrast to the Zacks S&P 500 composite's +2.4% move. With a Zacks Rank #2 (Buy), TMO is expected outperform the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
Beyond Nvidia: AI's Second Wave Is Here
The AI revolution has already minted millionaires. But the stocks everyone knows about aren't likely to keep delivering the biggest profits. AI’s second wave is moving from infrastructure to implementation and these companies are at the forefront of this transition, positioned to become what Amazon and Google were to the internet era.
See Stocks Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Thermo Fisher Scientific Inc. (TMO): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).